Robert-Jan van Geuns

Robert-Jan van Geuns

Auto-generated profile, based on publicly available information

Robert-Jan van Geuns

Department of Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
MKMatthijs van Kranenburg
Matthijs van Kranenburg
MMMichael Magro
Michael Magro
HTHolger Thiele
Holger Thiele
SWSuzanne de Waha
Suzanne de Waha
IEIngo Eitel
Ingo Eitel
RGRobert-Jan van Geuns
Robert-Jan van Geuns

7 October 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
ABAdrian P. Banning
Adrian P. Banning
PSPatrick Serruys
Patrick Serruys
MTMaria Giovanna Trivieri
Maria Giovanna Trivieri
NRNicola Ryan
Nicola Ryan
SWSimon Walsh
Simon Walsh
JEJavier Escaned
Javier Escaned
The SYNTAX II study evaluated the impact of advances in percutaneous coronary intervention (PCI), integrated into a single revascularization strategy, on outcomes of patients with de novo three-vessel disease. The study employed decision-making utilizing the SYNTAX score II, use of coronary physiology, thin-strut biodegradable polymer drug-eluting stents, intravascular ultrasound, enhanced treatments of chronic total occlusions, and optimized medical therapy. Patients treated with this approach were compared with predefined patients from the SYNTAX I trial. SYNTAX II was a multicentre, single-arm, open-label study of patients requiring revascularization who demonstrated clinical equipoise for treatment with either coronary artery bypass grafting (CABG) or PCI, predicted by the SYNTAX score II. The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE), which included any revascularization. The comparators were a matched PCI cohort trial and a matched CABG cohort, both from the SYNTAX I trial. At 5 years, MACCE rate in SYNTAX II was significantly lower than in the SYNTAX I PCI cohort (21.5% vs. 36.4%, P < 0.001). This reflected lower rates of revascularization (13.8% vs. 23.8%, P < 0.001), and myocardial infarction (MI) (2.7% vs. 10.4%, P < 0.001), consisting of both procedural MI (0.2% vs. 3.8%, P < 0.001) and spontaneous MI (2.3% vs. 6.9%, P = 0.004). All-cause mortality was lower in SYNTAX II (8.1% vs. 13.8%, P = 0.013) reflecting a lower rate of cardiac death (2.8% vs. 8.4%, P < 0.001). Major adverse cardiac and cerebrovascular events’ outcomes at 5 years among patients in SYNTAX II and predefined patients in the SYNTAX I CABG cohort were similar (21.5% vs. 24.6%, P = 0.35). Use of the SYNTAX II PCI strategy in patients with de novo three-vessel disease led to improved and durable clinical results when compared to predefined patients treated with PCI in the original SYNTAX I trial. A predefined exploratory analysis found no significant difference in MACCE between SYNTAX II PCI and matched SYNTAX I CABG patients at 5-year follow-up. Comparison of outcomes after PCI using either the Syntax or Syntax 2 strategies.

1 January 2011 in Journal of Cardiovascular Magnetic Resonance
Verified
Journal Article
Open access
PDF file
ARAlexia Rossi
Alexia Rossi
JCJerome Cornette
Jerome Cornette
MJMark R Johnson
Mark R Johnson
YKYusuf Karamermer
Yusuf Karamermer
TSTirza Springeling
Tirza Springeling
RGRobert-Jan M van Geuns
Robert-Jan M van Geuns
There are physiological reasons for the effects of positioning on hemodynamic variables and cardiac dimensions related to altered intra-abdominal and intra-thoracic pressures. This problem is especially evident in pregnant women due to the additional aorto-caval compression by the enlarged uterus. The purpose of this study was to investigate the effect of postural changes on cardiac dimensions and function during mid and late pregnancy using cardiovascular magnetic resonance (CMR).

6 January 2014 in European Heart Journal
Verified
Journal Article
Open access
PDF file
RDRoberto Diletti
Roberto Diletti
AKAntonios Karanasos
Antonios Karanasos
TMTakashi Muramatsu
Takashi Muramatsu
SNShimpei Nakatani
Shimpei Nakatani
NMNicolas M. Van Mieghem
Nicolas M. Van Mieghem
RGRobert Jan van Geuns
Robert Jan van Geuns
We evaluated the feasibility and the acute performance of the everolimus-eluting bioresorbable vascular scaffolds (BVS) for the treatment of patients presenting with ST-segment elevation myocardial infarction (STEMI). The present investigation is a prospective, single-arm, single-centre study, reporting data after the BVS implantation in STEMI patients. Quantitative coronary angiography and optical coherence tomography (OCT) data were evaluated. Clinical outcomes are reported at the 30-day follow-up. The intent-to-treat population comprises a total of 49 patients. The procedural success was 97.9%. Pre-procedure TIMI-flow was 0 in 50.0% of the patients; after the BVS implantation, a TIMI-flow III was achieved in 91.7% of patients and the post-procedure percentage diameter stenosis was 14.7 ± 8.2%. No patients had angiographically visible residual thrombus at the end of the procedure. Optical coherence tomography analysis performed in 31 patients showed that the post-procedure mean lumen area was 8.02 ± 1.92 mm2, minimum lumen area 5.95 ± 1.61 mm2, mean incomplete scaffold apposition area 0.118 ± 0.162 mm2, mean intraluminal defect area 0.013 ± 0.017 mm2, and mean percentage malapposed struts per patient 2.80 ± 3.90%. Scaffolds with >5% malapposed struts were 7. At the 30-day follow-up, target-lesion failure rate was 0%. Non-target-vessel revascularization and target-vessel myocardial infarction (MI) were reported. A non-target-vessel non-Q-wave MI occurred. No cases of cardiac death or scaffold thrombosis were observed. In the present series, the BVS implantation in patients presenting with acute MI appeared feasible, with high rate of final TIMI-flow III and good scaffold apposition. Larger studies are currently needed to confirm these preliminary data.

26 August 2023 in JACC
Verified
Journal Article
Closed access
FBFlavio G. Biccirè
Flavio G. Biccirè
JHJonas Häner
Jonas Häner
SLSylvain Losdat
Sylvain Losdat
YUYasushi Ueki
Yasushi Ueki
HSHiroki Shibutani
Hiroki Shibutani
LRLorenz Räber
Lorenz Räber

9 February 2023 in European Heart Journal
Verified
Journal Article
Open access
PDF file
CCCyril Camaro
Cyril Camaro
GAGoaris W A Aarts
Goaris W A Aarts
EAEddy M M Adang
Eddy M M Adang
RHRoger van Hout
Roger van Hout
GBGijs Brok
Gijs Brok
NRNiels Van Royen
Niels Van Royen
Patients with suspected non-ST-segment elevation acute coronary syndrome (NSTE-ACS) are routinely transferred to the emergency department (ED). A clinical risk score with point-of-care (POC) troponin measurement might enable ambulance paramedics to identify low-risk patients in whom ED evaluation is unnecessary. The aim was to assess safety and healthcare costs of a pre-hospital rule-out strategy using a POC troponin measurement in low-risk suspected NSTE-ACS patients. This investigator-initiated, randomized clinical trial was conducted in five ambulance regions in the Netherlands. Suspected NSTE-ACS patients with HEAR (History, ECG, Age, Risk factors) score ≤3 were randomized to pre-hospital rule-out with POC troponin measurement or direct transfer to the ED. The sample size calculation was based on the primary outcome of 30-day healthcare costs. Secondary outcome was safety, defined as 30-day major adverse cardiac events (MACE), consisting of ACS, unplanned revascularization or all-cause death. : A total of 863 participants were randomized. Healthcare costs were significantly lower in the pre-hospital strategy (€1349 ± €2051 vs. €1960 ± €1808) with a mean difference of €611 [95% confidence interval (CI): 353–869; P < 0.001]. In the total population, MACE were comparable between groups [3.9% (17/434) in pre-hospital strategy vs. 3.7% (16/429) in ED strategy; P = 0.89]. In the ruled-out ACS population, MACE were very low [0.5% (2/419) vs. 1.0% (4/417)], with a risk difference of −0.5% (95% CI −1.6%–0.7%; P = 0.41) in favour of the pre-hospital strategy. Pre-hospital rule-out of ACS with a POC troponin measurement in low-risk patients significantly reduces healthcare costs while incidence of MACE was low in both strategies. Clinicaltrials.gov identifier NCT05466591 and International Clinical Trials Registry Platform id NTR 7346. ACS, acute coronary syndrome; CI, confidence interval; ED, emergency department; MACE, major adverse cardiac events; NSTE-ACS, non-ST-elevation acute coronary syndrome; POC, point-of-care